May 11, 2021
Business News

Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

SOUTH SAN FRANCISCO, Calif.–()–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent business highlights and key catalysts over the next 18 months.

“Atara is off to a strong start in 2021, advancing all three strategic priorities to deliver on key value drivers,” said Pascal Touchon, President and Chief Executive Officer of Atara. “We look forward to several milestones in 2021, including the expected tab-cel® BLA and MAA…

Click here to view the original article.

Related Posts

You might also like ...

Pavilion Partners with Cyber Bytes Foundation to Provide High Speed Data Transfer and Storage Capabilities for Research and Innovation
Sensormatic Solutions by Johnson Controls Releases Spring 2021 U.S. Consumer Sentiment Survey
Lincoln Financial Group’s Heather Deichler Receives Women in Insurance Leadership: NEXT Award from Digital Insurance